Management of HER2 alterations in non-small cell lung cancer–the past, present, and future
HER2 mutations, which account for 2–4% of non-small cell lung cancer (NSCLC), are
distinct molecular alterations identified via next generation sequencing (NGS). Previously …
distinct molecular alterations identified via next generation sequencing (NGS). Previously …
Unraveling the future: innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy
S Zheng, R Chen, L Zhang, L Tan, L Li, F Long… - European Journal of …, 2024 - Elsevier
Human epidermal growth factor receptor 2 (HER2) is a transmembrane receptor-like protein
with tyrosine kinase activity that plays a vital role in processes such as cell proliferation …
with tyrosine kinase activity that plays a vital role in processes such as cell proliferation …
HER2-Positive Breast Cancer Treatment and Resistance
Abstract HER2-positive (+) breast cancer is an aggressive disease with poor prognosis, a
narrative that changed drastically with the advent and approval of trastuzumab, the first …
narrative that changed drastically with the advent and approval of trastuzumab, the first …